Cataract
Conditions
Brief summary
Patients with senile cataracts undergoing phacoemulsification were assigned to receive intracameral levofloxacin (0.1ml/0.5mg) or intracameral cefazolin (0.1ml/1mg). The primary endpoint was the occurrence of endophthalmitis during the 3 month follow-up period. Secondary endpoints included best-corrected visual acuity (BVCA), the presence of anterior chamber (AC) inflammation with grading of AC cells and presence of flare, along with intraocular pressure (IOP), corneal cell thickness (CCT), central foveal thickness (CFT) and cell density.
Interventions
DRUGSafety of intracameral levofloxacin in cataract surgery
Intracameral levofloxacin (0.1ml/0.5mg)
DRUGUse of intracameral cefazolin in cataract surgery
Intracameral cefazolin (0.1ml/1mg)
Sponsors
Tan Tock Seng Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Aged ≥50 to \<80 years * Undergoing cataract surgery under the care of one of three study investigators, all of whom were consultant level cataract surgeons * Only those with senile cataracts, assessed using the Lens Opacities Classification System III scale (LOCS III) and without features of complex cataracts were included
Exclusion criteria
* \<50 or \>80 years old * Prior ocular trauma, pregnant, previous history of refractive, corneal or intraocular surgery, cornea endothelial cell count \<1500/sqmm², concomitant ocular disease, allergy to penicillin, fluoroquinolone or cephalosporin, and abnormal biometric measurements
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of Participants with Treatment related adverse events to Intracameral Cefazolin versus Levofloxacin | From cataract surgery through to study completion, an average of 1 year |
Countries
Singapore
Outcome results
None listed